Rui Avelar - 10 May 2024 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer & Head of Research and Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol
EOLS
Transactions as of
10 May 2024
Net transactions value
-$43,761
Form type
4
Filing time
14 May 2024, 20:56:01 UTC
Previous filing
21 Mar 2024
Next filing
26 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Sale $43,761 -3,441 -0.92% $12.72 368,847 10 May 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 The shares were sold in multiple trades at prices ranging from $12.51 to $13.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer & Head of Research and Development